13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
37 檔
56.3%
According to the latest 13F quarterly dataset, Novo Holdings A/S managed an equity portfolio of $1.7B at the end of Q3 2024, spanning 37 distinct U.S. exchange-listed positions.
Novo Holdings A/S executed strategic sector rebalancing during Q3 2024, establishing 2 new positions while fully exiting 3 holdings and trimming 7 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VTI | Vanguard Total Stock Mkt ETF | ETF-Other | 14.61% | — | — | |
| 2 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 11.45% | — | — | |
| 3 | BN | Brookfield CORP | Stock-Financials | 9.22% | -2.78% | -10.03% | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 7.36% | -1.03% | -12.52% | |
| 5 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 5.54% | — | — | |
| 6 | ASML | ASML Holding N.V. | Stock-Tech | 5.52% | +0.81% | — | |
| 7 | CRM | Salesforce Inc | Stock-Tech | 5.01% | -2.37% | -23.24% | |
| 8 | PCVX | Vaxcyte Inc | Stock-Other | 4.26% | -1.35% | -21.05% | |
| 9 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.91% | -2.27% | — | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.69% | -0.89% | +19.25% | |
| 11 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.64% | -1.19% | — | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 2.63% | +0.75% | NEW | |
| 13 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.54% | -1.69% | — | |
| 14 | CABO | Cable One Inc | Stock-Comm Services | 2.06% | — | — | |
| 15 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.76% | -0.60% | +0.35% | |
| 16 | ✓ | Merus N V | Stock-Other | 1.74% | — | +3.70% | |
| 17 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.71% | -3.02% | EXIT | |
| 18 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.63% | -0.87% | +13.37% | |
| 19 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.62% | — | — | |
| 20 | PHVS | Pharvaris N.V. | Stock-Other | 1.59% | -1.20% | — | |
| 21 | ✓ | Lanzatech Global Inc | Stock-Other | 1.50% | — | — | |
| 22 | BAM | Brookfield Asset Mgmt-a | Stock-Financials | 1.47% | — | — | |
| 23 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.41% | — | — | |
| 24 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.33% | — | — | |
| 25 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.01% | — | — | |
| 26 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.97% | — | — | |
| 27 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.81% | -0.24% | +7.14% | |
| 28 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.80% | — | — | |
| 29 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 30 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.50% | — | -22.61% | |
| 31 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.45% | — | +5.71% | |
| 32 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 33 | IOBTQ | Io Biotech Inc | Stock-Other | 0.17% | — | -24.27% | |
| 34 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.15% | — | — | |
| 35 | MQ | Marqeta Inc-a | Stock-Other | 0.11% | +0.27% | — | |
| 36 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 37 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TEM | Tempus Ai Inc-cl A | +3.8% | — | Unchanged |
| 2 | CORT | Corcept Therapeutics Inc | +1.3% | — | Unchanged |
| 3 | VRDN | Viridian Therapeutics Inc | +1.3% | +19.25% | Add |
| 4 | EWTX | Edgewise Therapeutics Inc | +1.2% | -12.52% | Trim |
| 5 | ZBIO | Zenas Biopharma Inc | +1% | NEW | New buy |
| 6 | BABA | Alibaba Group Holding-sp Adr | +0.7% | — | Unchanged |
| 7 | BN | Brookfield CORP | +0.5% | -10.03% | Trim |
| 8 | PCVX | Vaxcyte Inc | +0.4% | -21.05% | Trim |
| 9 | AVBP | Arrivent Biopharma Inc | +0.3% | +0.35% | Add |
| 10 | BAM | Brookfield Asset Mgmt-a | +0.2% | — | Unchanged |
| 11 | MIRM | Mirum Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 12 | CRNX | Crinetics Pharmaceuticals In | +0.1% | — | Unchanged |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 14 | DMRA | Damora Therapeutics Inc | +0.1% | NEW | New buy |
| 15 | CRGX | Cargo Therapeutics Inc | 0% | — | Unchanged |
| 16 | SPRO | Spero Therapeutics Inc | — | — | Unchanged |
| 17 | AM6 | Amicus Therapeutics Inc | 0% | — | Unchanged |
| 18 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 19 | ABCL | Abcellera Biologics Inc | 0% | — | Unchanged |
| 20 | ✓ | Verve Therapeutics Inc | -0.1% | — | Unchanged |
| 21 | GLTOUSD | Damora Therapeutics Inc | -0.1% | EXIT | Sold out |
| 22 | CLDX | Celldex Therapeutics Inc | -0.1% | +13.37% | Add |
| 23 | ✓ | Lanzatech Global Inc | -0.1% | — | Unchanged |
| 24 | IOBTQ | Io Biotech Inc | -0.1% | -24.27% | Trim |
| 25 | PHVS | Pharvaris N.V. | -0.2% | — | Unchanged |
| 26 | CABO | Cable One Inc | -0.2% | — | Unchanged |
| 27 | MGX | Metagenomi Therapeutics Inc | -0.2% | — | Unchanged |
| 28 | 2655787D | Blueprint Medicines CORP | -0.2% | — | Unchanged |
| 29 | KYTX | Kyverna Therapeutics Inc | -0.3% | +5.71% | Add |
| 30 | INSM | Insmed Inc | -0.3% | -9.42% | Trim |
| 31 | RCKT | Rocket Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 32 | VTI | Vanguard Total Stock Mkt ETF | -0.4% | — | Unchanged |
| 33 | ✓ | Merus N V | -0.4% | +3.70% | Add |
| 34 | BMRN | Biomarin Pharmaceutical Inc | -0.5% | — | Unchanged |
| 35 | MORFUSD | Morphic Holding Inc | -0.7% | EXIT | Sold out |
| 36 | LXEO | Lexeo Therapeutics Inc | -0.8% | -22.61% | Trim |
| 37 | FDMT | 4d Molecular Therapeutics In | -0.8% | +7.14% | Add |
| 38 | CRM | Salesforce Inc | -1.7% | -23.24% | Trim |
| 39 | ASML | ASML Holding N.V. | -1.8% | — | Unchanged |
| 40 | AAPL | Apple Inc | -2.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 37 disclosed positions in Q3 2024.
During Q3 2024, Novo Holdings A/S's top holdings by market value included VTI (14.6%)、TEM (11.4%)、BN (9.2%). The largest single position, VTI, represented 14.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VTI, TEM, BN) accounted for 56.3% of total reported equity market value during Q3 2024.
Top New Position Initiated
ZBIO
市值: $19.5M
Top Position Liquidated / Trimmed
AAPL
前期市值: $38.5M
In Q3 2024, Novo Holdings A/S made 18 total portfolio adjustments, initiating 2 new buys, adding to 6 positions, trimming 7 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.